8 min read
Monthly FDA Guidance and Regulatory News Review - August 2026
This August 2026 regulatory update focuses on the FDA finalizing three guidances addressing formal sponsor meetings,...
Meet Veristat at the 2025 ASCO Annual Meeting
Advancing Oncology Therapies for Patients in Need
Veristat is proud to participate in the 2025 ASCO Annual Meeting, the world’s leading oncology event, taking place May 30 – June 3 at McCormick Place in Chicago, IL, and online. This must-attend global gathering brings together oncology professionals to explore breakthrough science, cutting-edge technology, and the future of cancer care.
Your Oncology Development Partner
At Veristat, we specialize in advancing novel oncology therapies from early clinical development through to regulatory approval. With more than 30 years of experience, our cross-functional teams deliver creative and strategic solutions that help sponsors overcome complex regulatory and operational hurdles—accelerating the path to market and improving outcomes for patients.
Tailored Strategies and Expert Insights
Veristat brings deep experience to cancer therapy development programs. In the past five years, we’ve:
-
Supported 480+ oncology and hematology studies
-
Prepared 70+ INDs and CTAs
- Led 30+ US and European regulatory marketing applications
From first-in-human studies to global marketing submissions, our oncology experts design smarter trials, navigate accelerated pathways, and ensure data and strategy align for regulatory success.
Meet with Veristat :
Gabriela Rosu – Vice President, Global Medical Affairs and Pharmacovigilance
Parris Johnson – Senior Business Development Director
Mandy McCormick – Business Development Manager
Schedule a meeting with our team to discuss how Veristat can help advance your oncology development program and bring your therapies to patients faster.
Learn more about the conference
8 min read
Monthly FDA Guidance and Regulatory News Review - July 2026
Aug 14, 2026 Veristat Blog
This July 2026 regulatory update focuses on the FDA finalizing six guidances that addresses antiviral next-generation...